# Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

> **NCT05929664** · PHASE2 · RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 70 (estimated)

## Conditions studied

- Locally Advanced Basal Cell Carcinoma
- Basal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Cemiplimab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biopsy
- **BIOLOGICAL:** Fianlimab

## Key facts

- **NCT ID:** NCT05929664
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-05
- **Primary completion:** 2031-07-05
- **Final completion:** 2031-07-05
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05929664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05929664, "Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05929664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*